Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881840 | 0.88 | MCHR1 (0.47) | MCHR1DDR1EPHX2CHRM1CNR1 | |
| SCHEMBL4913349 | 0.86 | TRPV1 (0.52) | TRPV1DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3944534 | 0.82 | TRPV1 (0.44) | TRPV1DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3952036 | 0.79 | CNR1 (0.43) | MCHR1CNR1CNR2 | |
| SCHEMBL3110196 | 0.77 | DPP4 (0.48) | DDR1EPHX2NR1H4GCGRCNR1 | |
| SCHEMBL3879970 | 0.76 | OPRL1 (0.43) | MCHR1CNR1CNR2 | |
| SCHEMBL4513493 | 0.76 | CNR1 (0.45) | MCHR1CNR1CNR2 | |
| SCHEMBL3111640 | 0.75 | CNR1 (0.44) | DDR1EPHX2NR1H4GCGRCNR1 | |
| SCHEMBL3113188 | 0.74 | PPARD (0.44) | DDR1EPHX2NR1H4GCGRCNR1 | |
| SCHEMBL3107295 | 0.74 | CNR1 (0.47) | DDR1EPHX2NR1H4GCGRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS | 2009-08-13 | — | — | US | disclosed |
| EP-2010492-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119001-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | TPMT, QDPR, HNMT | TRPV1 824/4885MCHR1 3441/4885ACHE 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.